Key facts
- Pinteon Therapeutics’s last known valuation is $28.0M (Oct 2019).
- It has raised $46.2M across 2 recorded rounds; the latest was Early Stage VC ($29.2M) in Jan 2022.
- Notable investors include Morningside Group, Advanced Technology International, LabCentral.
- Pinteon Therapeutics has filed 7 Form Ds with the SEC since 2014, most recently Nov 2025 ($29.2M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pinteon Therapeutics
Funding rounds
2 roundsAbout Pinteon Therapeutics
Developer of a novel antibody intended to maintain the brain health of patients. The company's antibody interrupts the spread of toxic tau and protects and preserves brain function in patients suffering from neurodegenerative disease, enabling doctors to normalize aberrant disease processes and improve patient outcomes in these high-unmet medical needs indications.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2014
- Employees
- 3
- Website
- pinteon.com/
- Ownership
- Privately Held (backing)
Pinteon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pinteon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pinteon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.